Palemo控股
2778
Spancrete
5277
Renascience
4889
Oncolys BioPharma
4588
北川精機
6327
(FY)2024/03/31 | (Q4)2024/03/31 | (Q3)2023/12/31 | (Q2)2023/09/30 | (Q1)2023/06/30 | (FY)2023/03/31 | (Q4)2023/03/31 | (Q3)2022/12/31 | (Q2)2022/09/30 | (Q1)2022/06/30 | |
---|---|---|---|---|---|---|---|---|---|---|
營業總收入 | 1.66%317.75億 | 9.55%73.49億 | -2.58%78.4億 | -1.05%84.68億 | 2.22%81.17億 | 10.39%312.56億 | 3.01%67.09億 | 19.31%80.48億 | 14.13%85.58億 | 5.08%79.41億 |
主營業務成本 | 1.50%285.11億 | 9.01%66.03億 | -2.11%71.14億 | -1.58%75.72億 | 2.11%72.21億 | 10.90%280.9億 | 2.16%60.58億 | 20.18%72.68億 | 14.90%76.93億 | 6.23%70.72億 |
毛利 | 3.14%32.65億 | 14.54%7.46億 | -6.88%7.27億 | 3.62%8.97億 | 3.11%8.96億 | 6.09%31.65億 | 11.70%6.51億 | 11.78%7.8億 | 7.67%8.65億 | -3.37%8.69億 |
營業費用 | 3.73%23.06億 | 0.44%5.53億 | 1.19%5.59億 | 5.68%5.84億 | 7.51%6.09億 | 3.05%22.23億 | 4.98%5.51億 | 6.90%5.53億 | -3.40%5.53億 | 4.31%5.67億 |
營業利潤 | 1.74%9.59億 | 91.73%1.93億 | -26.49%1.67億 | -0.01%3.12億 | -5.15%2.86億 | 14.05%9.42億 | 72.02%1.01億 | 25.73%2.27億 | 35.04%3.12億 | -15.10%3.02億 |
營業外利息收入與支出淨額 | -29.68%-1,128.7萬 | -23.44%-313.9萬 | -41.48%-282.4萬 | -32.83%-263.8萬 | -23.27%-268.6萬 | -22.13%-870.4萬 | -50.38%-254.3萬 | -19.38%-199.6萬 | -18.36%-198.6萬 | -4.46%-217.9萬 |
營業外利息收入 | -20.49%55.5萬 | -17.92%14.2萬 | -22.49%13.1萬 | ---- | ---- | -14.98%69.8萬 | -15.20%17.3萬 | -15.92%16.9萬 | ---- | ---- |
營業外利息支出 | 25.95%1,184.2萬 | 20.80%328.1萬 | 36.49%295.5萬 | 24.68%292萬 | 23.27%268.6萬 | 18.29%940.2萬 | 43.32%271.6萬 | 15.59%216.5萬 | 11.84%234.2萬 | 4.46%217.9萬 |
投資淨收益 | 15.73%-6,046.6萬 | -1.16%-1,315.7萬 | 81.40%-278.6萬 | -216.28%-1,463.1萬 | 23.63%-2,989.2萬 | -1,364.69%-7,175.5萬 | 18.99%-1,300.6萬 | -836.48%-1,498萬 | -127.89%-462.6萬 | -424.28%-3,914.3萬 |
被指定為現金流套期的金融工具損益 | ||||||||||
終止確認可供出售金融資產損益 | 9,192.4萬 | 0 | 8,564.4萬 | 516萬 | 112萬 | 0 | 0 | 0 | 0 | 0 |
聯營企業及其他參股權益產生的收益 | ||||||||||
特殊收入(費用) | 384.4萬 | 0 | -613.3萬 | 0 | 0 | 0 | ||||
減:其他特殊費用 | ---384.4萬 | --0 | --613.3萬 | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
其他營業外收入(費用) | 72.00%2,265.4萬 | -58.49%160.2萬 | 248.50%1,417.7萬 | -42.81%149.6萬 | 104.68%537.9萬 | -50.22%1,317.1萬 | -19.23%385.9萬 | -45.32%406.8萬 | -56.59%261.6萬 | -68.02%262.8萬 |
稅前利潤 | 14.90%10.05億 | 100.41%1.78億 | 18.98%2.55億 | 1.08%3.12億 | -1.11%2.6億 | 2.94%8.75億 | 71.58%8,889.1萬 | 13.70%2.15億 | 20.77%3.08億 | -25.70%2.63億 |
所得稅 | 13.04%3.09億 | 117.13%4,344.5萬 | 1.63%7,753.3萬 | 12.13%1.09億 | -0.90%7,992.6萬 | 4.08%2.74億 | 1.05%2,000.9萬 | 37.03%7,629.3萬 | 20.79%9,681.8萬 | -24.91%8,065.1萬 |
除稅後利潤 | 15.75%6.96億 | 95.55%1.35億 | 28.55%1.78億 | -3.98%2.03億 | -1.21%1.8億 | 2.43%6.01億 | 115.23%6,888.3萬 | 3.94%1.38億 | 20.77%2.12億 | -26.05%1.82億 |
持續經營利潤 | 15.75%6.96億 | 95.55%1.35億 | 28.55%1.78億 | -3.98%2.03億 | -1.21%1.8億 | 2.43%6.01億 | 115.23%6,888.2萬 | 3.94%1.38億 | 20.77%2.12億 | -26.05%1.82億 |
歸屬于少數股東的淨利潤 | -30.62%1,446.6萬 | 422.26%317.1萬 | -38.42%584.7萬 | -78.51%155.1萬 | -23.89%389.7萬 | 80.26%2,084.9萬 | 61.50%-98.4萬 | 42.95%949.5萬 | 40.40%721.8萬 | 118.90%512萬 |
歸屬於母公司的淨利潤 | 17.41%6.82億 | 88.26%1.32億 | 33.49%1.72億 | -1.35%2.02億 | -0.55%1.76億 | 0.86%5.8億 | 102.16%6,986.7萬 | 1.89%1.29億 | 20.17%2.04億 | -27.44%1.77億 |
優先股派息 | ||||||||||
其他優先股派息 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
歸屬于普通股股東的淨利潤 | 17.41%6.82億 | 88.26%1.32億 | 33.49%1.72億 | -1.35%2.02億 | -0.55%1.76億 | 0.86%5.8億 | 102.16%6,986.7萬 | 1.89%1.29億 | 20.17%2.04億 | -27.44%1.77億 |
總派息金額 | ||||||||||
基本每股收益 | 19.75%220.69 | 99.64%44.28 | 37.85%56.38 | -1.34%64.04 | -0.55%55.99 | 0.86%184.29 | 102.19%22.18 | 1.92%40.9 | 20.16%64.91 | -27.44%56.3 |
稀釋每股收益 | 19.75%220.69 | 98.36%43.9951 | 37.88%56.38 | -1.34%64.04 | -0.55%55.99 | 0.86%184.29 | 102.19%22.18 | 1.90%40.8919 | 20.17%64.91 | -27.44%56.3 |
每股派息 | 6.38%50 | 6.38%50 | 0 | 0 | 0 | 0.00%47 | 0.00%47 | 0 | 0 | 0 |
貨幣單位 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 |
會計準則 | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |